Management Strategies for Ribavirin-Induced Hemolytic Anemia in the Treatment of Hepatitis C: Clinical and Economic Implications
- 1 September 2001
- journal article
- review article
- Published by Elsevier in Value in Health
- Vol. 4 (5) , 376-384
- https://doi.org/10.1046/j.1524-4733.2001.45075.x
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alphaTransplantation Proceedings, 1999
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis CNew England Journal of Medicine, 1998
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusPublished by Elsevier ,1998
- Hepatitis C: The clinical spectrum of diseaseHepatology, 1997
- Therapy of hepatitis C: OverviewHepatology, 1997
- Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantationHepatology, 1997
- Meta–Analysis of Interferon Randomized Trials in the Treatment of Viral Hepatitis C: Effects of Dose and DurationHepatology, 1996
- A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B HepatitisNew England Journal of Medicine, 1995